Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China and internationally. The company offers rapid test kits for COVID-19, drug of abuse, tumor marker, infectious disease, fertility, blood/serum/plasma test, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease, as well as Finecare FIA Meter X2, a 16-channel fluorescence immunoassay analyzing system; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; blood gas biochemical analyzers and blood gas analyzers; molecular diagnostics platform; pathology straining system; and HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution. Its products are used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. The company was founded in 1992 and is based in Guangzhou, China.
